Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$103.46 - $126.29 $7.76 Million - $9.47 Million
75,000 Added 57.52%
205,400 $22 Million
Q4 2022

Feb 14, 2023

BUY
$36.06 - $117.21 $4.7 Million - $15.3 Million
130,400 New
130,400 $14.3 Million

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Capital World Investors Portfolio

Follow Capital World Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.